These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9606451)

  • 1. Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.
    Bever KA; Perry PJ
    Am J Health Syst Pharm; 1998 May; 55(10):1003-16. PubMed ID: 9606451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine: an atypical antipsychotic for schizophrenia.
    Lund BC; Perry PJ
    Expert Opin Pharmacother; 2000 Jan; 1(2):305-23. PubMed ID: 11249551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia.
    Kando JC; Shepski JC; Satterlee W; Patel JK; Reams SG; Green AI
    Ann Pharmacother; 1997 Nov; 31(11):1325-34. PubMed ID: 9391688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics.
    Borison RL
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):24S-29S. PubMed ID: 7537285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.
    Fulton B; Goa KL
    Drugs; 1997 Feb; 53(2):281-98. PubMed ID: 9028746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine. Keep an eye on this neuroleptic.
    Can Fam Physician; 2000 Feb; 46():322-6, 330-6. PubMed ID: 10690489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical efficacy of olanzapine].
    Yui K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Jul; 19(3):101-10. PubMed ID: 10495984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine for schizophrenia.
    Duggan L; Fenton M; Dardennes RM; El-Dosoky A; Indran S
    Cochrane Database Syst Rev; 2000; (2):CD001359. PubMed ID: 10796640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ondansetron for tardive dyskinesia.
    Zullino DF; Eap CB; Voirol P
    Am J Psychiatry; 2001 Apr; 158(4):657-8. PubMed ID: 11282718
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia.
    Andersson C; Chakos M; Mailman R; Lieberman J
    Psychiatr Clin North Am; 1998 Mar; 21(1):151-79. PubMed ID: 9551495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
    Gothelf D; Apter A; Reidman J; Brand-Gothelf A; Bloch Y; Gal G; Kikinzon L; Tyano S; Weizman R; Ratzoni G
    J Neural Transm (Vienna); 2003 May; 110(5):545-60. PubMed ID: 12721815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral pharmacology of olanzapine: a novel antipsychotic drug.
    Moore NA; Leander JD; Benvenga MJ; Gleason SD; Shannon H
    J Clin Psychiatry; 1997; 58 Suppl 10():37-44. PubMed ID: 9265915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.
    Baker RW; Ames D; Umbricht DS; Chengappa KN; Schooler NR
    Psychopharmacol Bull; 1996; 32(1):89-93. PubMed ID: 8927681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of olanzapine: an overview of pivotal clinical trials.
    Beasley CM; Tollefson GD; Tran PV
    J Clin Psychiatry; 1997; 58 Suppl 10():7-12. PubMed ID: 9265910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.